Literature DB >> 14737098

p53 protein variants: structural and functional similarities with p63 and p73 isoforms.

Stéphanie Courtois1, Claude Caron de Fromentel, Pierre Hainaut.   

Abstract

Since its discovery in 1979, many studies have reported that the p53 tumour suppressor protein could be expressed in the form of products smaller than those predicted by the full-length amino-acid sequence. These products differ from full-length p53 in their N- or C-terminal regions, but generally conserve the central, DNA-binding domain. They appear to be expressed at rather low levels and to be restricted to particular cell types and/or physiological circumstances, suggesting that they play very narrow and specific roles. Several mechanisms have been proposed to explain their timely occurrence, including alternative splicing, internal initiation of translation or proteolytic cleavage. A precise assessment of the various 'p53 isoforms' reveals striking similarities with several isoforms of the p53 homologous proteins p63 or p73, suggesting that regulated production of specific, N- or C-terminal variants may be a 'trademark' of all family members. In this review, we summarize the published evidence on the structure, mode of production, expression and function of the p53 isoforms, and discuss their properties in the light of recent data on the structure and function of p63/p73 isoforms.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14737098     DOI: 10.1038/sj.onc.1206929

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  30 in total

1.  Structural genomics analysis of alternative splicing and application to isoform structure modeling.

Authors:  Peng Wang; Bo Yan; Jun-Tao Guo; Chindo Hicks; Ying Xu
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-14       Impact factor: 11.205

Review 2.  Transcriptional control of terminal nephron differentiation.

Authors:  Samir S El-Dahr; Karam Aboudehen; Zubaida Saifudeen
Journal:  Am J Physiol Renal Physiol       Date:  2008-02-20

Review 3.  The Role of the p53 Protein in Stem-Cell Biology and Epigenetic Regulation.

Authors:  Arnold J Levine; Anna M Puzio-Kuter; Chang S Chan; Pierre Hainaut
Journal:  Cold Spring Harb Perspect Med       Date:  2016-09-01       Impact factor: 6.915

4.  The C terminus of p53 family proteins is a cell fate determinant.

Authors:  Kelly Lynn Harms; Xinbin Chen
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

Review 5.  Tumor suppression by p53: making cells senescent.

Authors:  Yingjuan Qian; Xinbin Chen
Journal:  Histol Histopathol       Date:  2010-04       Impact factor: 2.303

6.  Non-small cell lung cancer is susceptible to induction of DNA damage responses and inhibition of angiogenesis by telomere overhang oligonucleotides.

Authors:  Neelu Puri; Ryan T Pitman; Richard E Mulnix; Terrianne Erickson; Audra N Iness; Connie Vitali; Yutong Zhao; Ravi Salgia
Journal:  Cancer Lett       Date:  2013-09-14       Impact factor: 8.679

Review 7.  Overexpression of p53 protein in human tumors.

Authors:  Keiji Inoue; Atsushi Kurabayashi; Taro Shuin; Yuji Ohtsuki; Mutsuo Furihata
Journal:  Med Mol Morphol       Date:  2012-09-22       Impact factor: 2.309

Review 8.  Somatic TP53 Mutations in the Era of Genome Sequencing.

Authors:  Pierre Hainaut; Gerd P Pfeifer
Journal:  Cold Spring Harb Perspect Med       Date:  2016-11-01       Impact factor: 6.915

9.  Expression levels of p53 and p73 isoforms in stage I and stage III ovarian cancer.

Authors:  Mirko Marabese; Sergio Marchini; Eleonora Marrazzo; Pietro Mariani; Dario Cattaneo; Roldano Fossati; Anna Compagnoni; Mauro Signorelli; Ute M Moll; A Maria Codegoni; Massimo Broggini
Journal:  Eur J Cancer       Date:  2007-11-26       Impact factor: 9.162

10.  Regulation of p53 expression, phosphorylation and subcellular localization by a G-protein-coupled receptor.

Authors:  L Solyakov; E Sayan; J Riley; A Pointon; A B Tobin
Journal:  Oncogene       Date:  2009-08-03       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.